Cybin Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | no data |
| CEO ownership | n/a |
| Management average tenure | 5.3yrs |
| Board average tenure | 5.4yrs |
Recent management updates
Recent updates
Narrative Update • Jul 24
HELP: Phase 3 Depression Readout And Cash Raise Will Drive Repricing
Analysts have reduced their price target on Cybin to reflect a lower fair value estimate of about $37.57. This adjustment is offset by expectations for very large future revenue growth, supported by a reduced future P/E assumption and only modest changes to profit margin and discount rate inputs.Seeking Alpha • Jul 12
Helus Pharma: APPROACHing Inflection: Pivotal Readout Sets Up Asymmetric Upside
Summary I initiate coverage of Helus Pharma with a speculative Buy, citing an attractive high-risk/high-reward setup ahead of the pivotal Phase 3 APPROACH readout in Q4 2026. HELP’s lead asset HLP003, an oral deuterated psilocin analog for adjunctive MDD, shows compelling Phase 2 efficacy, FDA Breakthrough Therapy Designation, and a differentiated clinical profile. Current valuation (~$269M EV, ~$207M pro forma cash) under-credits the probability-weighted value of HLP003, with a risk-adjusted implied EV of ~$1.5B if Phase 3 succeeds. Risks include functional unblinding, commercial launch hurdles, and potential dilution, but cash runway appears sufficient for near-term catalysts and positive data could drive a material re-rating. Read the full article on Seeking Alpha
Narrative Update • Jul 10
HELP: Sector Depression Trial Milestones Will Shape This Psychedelic Undervaluation View
Analysts have reduced their price target for Cybin to reflect a revised fair value estimate of about $70.05, citing updated views on long term revenue potential, profit margins, and an adjusted future P/E outlook informed by recent psychedelic sector research on comparable late stage drug developers. Analyst Commentary Recent sector research on late stage psychedelic drug developers is shaping how bullish analysts think about Cybin, especially when they compare it with peers working on deuterated psilocin and similar compounds.
Narrative Update • Jun 26
HELP: Policy Momentum On PTSD Treatments Will Drive Future Psychedelic Therapy Demand
Analysts have lowered their Cybin price targets to around $7.78 from about $22.14, citing updated assumptions that include a somewhat higher discount rate, slightly softer long term profit margins, and a reduced but still very large future P/E multiple, partly offset by higher projected revenue growth. What’s in the News for Cybin Cybin completed a follow on equity offering of approximately $50.0 million, issuing 10,309,280 common shares at a price of $4.85 per share, with a stated discount of $0.291 per security.Analysis Article • Jun 17
We Think Cybin (NASDAQ:HELP) Needs To Drive Business Growth Carefully
Just because a business does not make any money, does not mean that the stock will go down. For example, although...New Narrative • Apr 05
Psychedelic Therapy Trials Will Face Cash Strain Yet Could Unlock Long Term Upside
Catalysts About Cybin Cybin is a clinical stage biopharmaceutical company developing psychedelic based therapies for major depressive disorder and generalized anxiety disorder. What are the underlying business or industry changes driving this perspective?New Narrative • Mar 22
Late Stage Psychedelic Therapies And Clinic Partnerships Will Reshape Treatment For Depression And Anxiety
Catalysts About Cybin Cybin is a clinical stage biopharmaceutical company developing psychedelic based therapies for major depressive disorder and generalized anxiety disorder. What are the underlying business or industry changes driving this perspective?New Narrative • Mar 05
Interventional Psychiatry And Clinic Partnerships Will Support Long Term Psychedelic Treatment Adoption
Catalysts About Cybin Cybin is a clinical stage company developing psychedelic based treatments for major depressive disorder and generalized anxiety disorder. What are the underlying business or industry changes driving this perspective?CEO
Cybin has no CEO, or we have no data on them.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 5.8yrs | US$6.84m | 5.13% $ 29.5m | |
| Co-Founder | no data | US$6.84m | 5.07% $ 29.2m | |
| Chief Financial Officer | 5.8yrs | US$1.00m | 0.14% $ 805.2k | |
| Chief Legal Officer & Corporate Secretary | 5.8yrs | US$1.12m | 0.18% $ 1.0m | |
| Chief Business Officer | 2.8yrs | US$843.49k | 0.060% $ 346.8k | |
| Co-Founder | no data | US$1.19m | no data | |
| Chief Operating Officer | 3.1yrs | US$764.06k | 0.28% $ 1.6m | |
| Chief Scientific Officer | 5.7yrs | no data | no data | |
| Chief Compliance | 4.8yrs | no data | no data | |
| Chief Communications Officers | no data | no data | no data | |
| Chief Pharmaceutical Strategist | no data | no data | no data | |
| Senior Vice President of Clinical Operations | 4.6yrs | no data | no data |
5.3yrs
Average Tenure
50yo
Average Age
Experienced Management: HELP's management team is seasoned and experienced (5.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 5.8yrs | US$6.84m | 5.13% $ 29.5m | |
| Co-Founder | 5.8yrs | US$6.84m | 5.07% $ 29.2m | |
| Member of Scientific Advisory Board | less than a year | no data | no data | |
| Lead Independent Director | 5yrs | US$286.56k | 0.10% $ 578.2k | |
| Director & Chair of Scientific Advisory Committee | less than a year | no data | 0.16% $ 928.0k | |
| Independent Director | 5.8yrs | US$291.77k | 0.21% $ 1.2m | |
| Independent Director | 5.8yrs | US$271.58k | 0.21% $ 1.2m | |
| Member of Scientific Advisory Board | less than a year | no data | no data | |
| Member of Scientific Advisory Board | less than a year | no data | no data | |
| Independent Director | 5.8yrs | US$271.58k | 0.21% $ 1.2m |
5.4yrs
Average Tenure
64.5yo
Average Age
Experienced Board: HELP's board of directors are considered experienced (5.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/05 09:42 |
| End of Day Share Price | 2026/08/05 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cybin Inc. is covered by 15 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| David Martin | Bloom Burton & Co. |
| Sumant Satchidanand Kulkarni | Canaccord Genuity |